Horizon Pharma

Horizon Pharma Plc
Public limited company
Traded as NASDAQ: HZNP
Russell 2000 Component
Industry Pharmaceuticals
Founded 2005
Headquarters Dublin, Ireland
Key people

Timothy P. Walbert (Chairman, President & CEO)
Paul W. Hoelscher (CFO)
Robert F. Carey (CBO)

Jeffrey W. Sherman, M.D. (CMO)
Revenue Increase $1.056 billion(2017)
Decrease$264 million (2014)[1]
Website www.horizonpharma.com

Horizon Pharma Public Limited Company (NASDAQ: HZNP) is an Irish pharmaceutical company that develops and markets medicines through its subsidiaries in the United States. The company was founded in 2005 and is based in Dublin, Ireland. The company focuses on developing treatments for arthritis, pain and inflammatory diseases.[2] Horizon's product portfolio includes Actimmune (interferon gamma), Duexis (ibuprofen + famotidine), Pennsaid (diclofenac, 2% topical), and Rayos/Lodotra (prednisone).[3] In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).[4]

Business

The company's lead product base includes Duexsis and Rayos. Outside the United States, Rayosis also known as Lodotra.[5]

The company has cooperated with American Gastroenterological Association (AGA) Institute to launch a program named "Connect to Protect" which aims to help physicians and patients better understand non-steroidal anti-inflammatory drug (NSAID) risks. The program is planned to promote communications between physicians and patients about NSAIDs and gastrointestinal ulcers.[6]

In March 2014, the company completed the acquisition of Vidara Therapeutics International through a merge valued at about $660 million.[7]

In October 2014, the company acquired the U.S. sales and marketing rights to the osteoarthritis drug Pennsaid from Nuvo Research for $45 million.[8]

In March 2015, the company acquired Hyperion Therapeutics for $1.1 billion, increasing Horizon's orphan disease drug portfolio.[9] In December, the company acquire Crealta Holdings for $510 million.[10]

In September 2016, the company announced the acquisition of Raptor Pharmaceutical for $800 million, adding Procysbi and Quinsair to its rare drug portfolio.[11]

In 2017, Horizon announced its intention to acquire River Vision Development Corp for $145 million, and continue the development of teprotumumab.[12]

References

  1. ↑ Horizon_Pharma_2014_Annual_Report_bmk.pdf
  2. ↑ "HZNP: Summary for Horizon Pharma Inc Common Stoc- Yahoo". Finance.Yahoo.com. Retrieved 23 March 2014.
  3. ↑ "HZNP Stock News". Company Description. Retrieved 5 December 2015.
  4. ↑ "Teva wins controversial PhRMA bid despite protests from branded rivals - FiercePharma". www.FiercePharma.com. Retrieved 26 August 2017.
  5. ↑ "Marketwatch of Horizon Pharma Inc". Marketwatch.com. Retrieved 21 March 2014.
  6. ↑ "Program introduction". ConnectToProtect.com. Retrieved 21 March 2014.
  7. ↑ "Horizon Pharma to Acquire Vidara Therapeutics International". Finance.yahoo.com. 19 March 2014. Retrieved 22 March 2014.
  8. ↑ "Horizon Pharma Picks Up Nuvo's Osteoarthritis Pain Drug Pennsaid 2% - GEN News Highlights - GEN". GEN.
  9. ↑ "Horizon Pharma to Acquire Hyperion Therapeutics for $1.1B". GEN.
  10. ↑ "Horizon Pharma Buys Crealta Holdings for $510M". GEN. Retrieved 30 April 2016.
  11. ↑ "Horizon Pharma to Acquire Raptor for $800M - GEN". GEN. Retrieved 26 August 2017.
  12. ↑ "BRIEF-Horizon Pharma Plc to acquire River Vision Development Corp". 8 May 2017. Retrieved 26 August 2017 – via Reuters.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.